Premium
Identification of genes differentially expressed in TLS‐CHOP carrying myxoid liposarcomas
Author(s) -
ThelinJärnum Sofia,
Lassen Carin,
Panagopoulos Ioannis,
Mandahl Nils,
Åman Pierre
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19990924)83:1<30::aid-ijc6>3.0.co;2-4
Subject(s) - biology , chop , gene , liposarcoma , myxoid liposarcoma , transcription factor , fusion gene , suppression subtractive hybridization , genetics , microbiology and biotechnology , cancer research , gene expression , pathology , sarcoma , medicine , endoplasmic reticulum , cdna library
Myxoid liposarcomas (MLS) carry a t(12;16) or, more rarely, a t(12;22) resulting in fusion of the transcription factor gene CHOP on chromosome 12 with TLS/FUS on chromosome 16 or EWS on chromosome 22. The chimeric TLS‐CHOP or EWS‐CHOP proteins most probably function as abnormal transcription factors, causing transcriptional de‐regulation of several target genes and relaxation of functions critical for growth and differentiation control. A PCR‐based subtractive hybridization technique was used to identify genes that are differentially expressed in TLS‐CHOP ‐carrying MLS but not in normal fat tissue. Six myxoid‐liposarcoma‐associated transcripts, MLAT, were isolated. The genes identified as MLAT can be divided into 2 groups. MLAT1, 2 and 6 show high similarity to glia‐derived nexin, neuronatin and the RET oncogene, respectively, all normally involved in development of tissues of neural origin. MLAT3 to MLAT5 represent new genes. Int. J. Cancer 83:30–33, 1999. © 1999 Wiley‐Liss, Inc.